Form 4: CRISPR CEO Kulkarni Reports RSU Vesting and Tax-Related Share Sale

CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover tax obligations.

Summary

• Samarth Kulkarni, CEO and Director of CRISPR Therapeutics AG, reported transactions involving company common shares.
• On March 14, 2026, 20,625 common shares were acquired upon the vesting of restricted stock units (RSUs).
• These acquired shares are part of an RSU award granted on March 14, 2025, for 82,500 common shares, vesting in four equal annual installments, with the first quarter vesting on March 14, 2026.
• Following this acquisition, Kulkarni beneficially owned 256,183 direct common shares.
• On March 16, 2026, Kulkarni sold 10,349 common shares at a price of $48.26 per share.
• This sale was mandated by the company's RSU Settlement Policy to cover tax withholding obligations related to the RSU vesting and was not a discretionary trade.
• After the sale, Kulkarni's direct beneficial ownership of common shares stands at 245,834.
• Kulkarni also holds 61,875 derivative securities in the form of Restricted Stock Units.
• The acquired shares remain subject to a lock-up agreement related to the Issuer's convertible senior notes due 2031.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine compensation-related transaction for the CEO, with no discretionary investment decision implied.

Positives

• The vesting of restricted stock units indicates continued long-term incentive alignment between the CEO and shareholder interests.

Negatives

• A portion of shares were sold, though this was a non-discretionary sale to cover tax obligations, which is a common practice.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the scheduled future vesting dates of the remaining restricted stock units.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and subsequent tax-related sales, are common across the biotechnology sector. These transactions typically reflect pre-scheduled compensation events rather than discretionary investment decisions, and are generally not indicative of a change in management's outlook on the company's prospects.

Related Party Transactions

• The reported transactions involve the CEO of CRISPR Therapeutics AG, making them related-party transactions (insider dealings).

Stakeholder Impact

• Shareholders: The sale of shares, while non-discretionary, slightly reduces the CEO's direct ownership percentage, but the overall impact is minimal given the routine nature of the transaction. The continued vesting of RSUs aligns executive incentives with long-term shareholder value.

Next Steps

• Remaining three-quarters of the RSU award (61,875 shares) are scheduled to vest in equal annual installments on March 14, 2027, March 14, 2028, and March 14, 2029.

Key Dates

Recommendation

The filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent non-discretionary sale of shares to cover tax obligations. This is a standard compensation event and does not indicate any change in the company's fundamentals or management's discretionary view on the stock's future performance. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

CRISPR Therapeutics, CRSP, Samarth Kulkarni, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Share Sale, Tax Withholding, Biotechnology, Gene Editing